Nonenantioselectivity property of human deoxycytidine kinase explained by structures of the enzyme in complex with L- and D-nucleosides

Journal of Medicinal Chemistry

Volumn 50, Issue 13, 2007, Pages 3004-3014

  Sabini, Elisabetta ^a   Hazra, Saugata ^a   Konrad, Manfred ^b   Lavie, Arnon ^a  

^a UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^b MAX PLANCK INSTITUTE FOR BIOPHYSICAL CHEMISTRY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; EMTRICITABINE; LAMIVUDINE; NUCLEOSIDE DERIVATIVE;

ARTICLE; CRYSTAL STRUCTURE; DRUG PROTEIN BINDING; ENANTIOMER; ENANTIOSELECTIVITY; ENZYME SPECIFICITY; ENZYME STRUCTURE; NONHUMAN;

DEOXYCYTIDINE; DEOXYCYTIDINE KINASE; HUMANS; LAMIVUDINE; MODELS, MOLECULAR; NUCLEOSIDES; PROTEIN CONFORMATION; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 34347230952     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm0700215     Document Type: Article

References (29)

1. Eriksson, S.; Munch-Petersen, B.; Johansson, K.; Eklund, H. Structure and function of cellular deoxyribonucleoside kinases. Cell. Mol. Life Sci. 2002, 59, 1327-1346.
2. Pasti, C.; Gallois-Montbrun, S.; Munier-Lehmann, H.; Veron, M.; Gilles, A. M.; Deville-Bonne, D. Reaction of human UMP-CMP kinase with natural and analog substrates. Eur. J. Biochem. 2003, 270, 1784-1790.
3. Krishnan, P.; Gullen, E. A.; Lam, W.; Dutschman, G. E.; Grill, S. P.; Cheng, Y. C. Novel role of 3-phosphoglycerate kinase, a glycolytic enzyme, in the activation of L-nucleoside analogs, a new class of anticancer and antiviral agents. J. Biol. Chem. 2003, 278, 36726-36732.
4. Feng, J. Y.; Anderson, K. S. Mechanistic studies examining the efficiency and fidelity of DNA synthesis by the 3TC-resistant mutant (184V) of HIV-1 reverse transcriptase. Biochemistry 1999, 38, 9440-9448.
5. Shafiee, M.; Griffon, J. F.; Gosselin, G.; Cambi, A.; Vincenzetti, S.; Vita, A.; Eriksson, S.; Imbach, J. L.; Maury, G. A comparison of the enantioselectivities of human deoxycytidine kinase and human cytidine deaminase. Biochem. Pharmacol. 1998, 56, 1237-1242.
6. Chang, C. N.; Doong, S. L.; Zhou, J. H.; Beach, J. W.; Jeong, L. S.; Chu, C. K.; Tsai, C. H.; Cheng, Y. C.; Liotta, D.; Schinazi, R. Deoxycytidine deaminase-resistant stereoisomer is the active form of (+/-)-2′,3′- dideoxy-3′-thiacytidine in the inhibition of hepatitis B virus replication. J. Biol. Chem. 1992, 267, 13938-13942.
7. Verri, A.; Focher, F.; Priori, G.; Gosselin, G.; Imbach, J. L.; Capobianco, M.; Garbesi, A.; Spadari, S. Lack of enantiospecificity of human 2′-deoxycytidine kinase: relevance for the activation of beta-L-deoxycytidine analogs as antineoplastic and antiviral agents. Mol. Pharmacol. 1997, 51, 132-138.
8. Maury, G. The enantioselectivity of enzymes involved in current antiviral therapy using nucleoside analogues: a new strategy? Antiviral Chem. Chemother. 2000, 11, 165-189.
9. Wang, J.; Chattopadhyaya, J.; Eriksson, S. The enantioselectivity of the cellular deoxynucleoside kinases. Nucleosides Nucleotides 1999, 18, 807-810.
10. Harrison, P. T.; Thompson, R.; Davison, A. J. Evolution of herpesvirus thymidine kinase from cellular deoxycytidine kinase. J. Gen. Virol. 1991, 72, 2583-2586.
11. Welin, M.; Kosinska, U.; Mikkelsen, N. E.; Carnrot, C.; Zhu, C.; Wang, L.; Eriksson, S.; Munch-Petersen, B.; Eklund, H. Structures of thymidine kinase 1 of human and mycoplasmic origin. Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 17970-17975.
12. Shewach, D. S.; Liotta, D. C.; Schinazi, R. F. Affinity of the antiviral enantiomers of oxathiolane cytosine nucleosides for human 2′-deoxycytidine kinase. Biochem. Pharmacol. 1993, 45, 1540-1543.
13. Gumina, G.; Chong, Y.; Choo, H.; Song, G.-Y.; Chu, C. L-Nucleosides: antiviral activity and molecular mechanism. Curr. Top. Med. Chem. 2002, 2, 1065-1086.
14. Weitman, S.; Marty, J.; Jolivet, J.; Locas, C.; Von Hoff, D. D. The new dioxolane, (-)-2′-deoxy-3′-oxacytidine (BCH-4556, troxacitabine), has activity against pancreatic human tumor xenografts. Clin. Cancer Res. 2000, 6, 1574-1578.
15. Gaubert, G.; Gosselin, G.; Boudou, V.; Imbach, J. L.; Eriksson, S.; Maury, G. Low enantioselectivities of human deoxycytidine kinase and human deoxyguanosine kinase with respect to 2′-deoxyadenosine, 2′-deoxyguanosine and their analogs. Biochimie 1999, 81, 1041-1047.
16. Gaubert, G.; Gosselin, G.; Imbach, J. L.; Eriksson, S.; Maury, G. Derivatives of L-adenosine and L-guanosine as substrates for human deoxycytidine kinase. Nucleosides Nucleotides 1999, 18, 857-860.
17. Tomikawa, A.; Kohgo, S.; Ikezawa, H.; Iwanami, N.; Shudo, K.; Kawaguchi, T.; Saneyoshi, M.; Yamaguchi, T. Chiral discrimination of 2′-deoxy- L-cytidine and L-nucleotides by mouse deoxycytidine kinase: low stereospecificities for substrates and effectors. Biochem. Biophys. Res. Commun. 1997, 239, 329-333.
18. Verri, A.; Priori, G.; Spadari, S.; Tondelli, L.; Focher, F. Relaxed enantioselectivity of human mitochondrial thymidine kinase and chemotherapeutic uses of L-nucleoside analogues. Biochem. J. 1997, 328, 317-320.
19. Sabini, E.; Hazra, S.; Konrad, M.; Burley, S. K.; Lavie, A. Structural basis for activation of the therapeutic L-nucleoside analogs 3TC and troxacitabine by human deoxycytidine kinase. Nucleic Acids Res. 2007, 35, 186-192.
20. Sabini, E.; Ort, S.; Monnerjahn, C.; Konrad, M.; Lavie, A. Structure of human dCK suggests strategies to improve anticancer and antiviral therapy. Nat. Struct. Biol. 2003, 10, 513-519.
21. Mahmoudian, M.; Baines, B. S.; Drake, C. S.; Hale, R. S.; Jones, P.; Piercey, J. E.; Montgomery, D. S.; Purvis, I. J.; Storer, R.; Dawson, M. J. Enzymatic production of optically pure (2′R-cis)-2′-deoxy- 3′-thiacytidine (3TC, lamivudine): a potent anti-HIV agent. Enzyme Microb. Technol. 1993, 15, 749-755.
22. Wang, J.; Choudhury, D.; Chattopadhyaya, J.; Eriksson, S. Stereoisomeric selectivity of human deoxyribonucleoside kinases. Biochemistry 1999, 38, 16993-16999.
23. Zhang, Y.; Secrist, J. A., 3rd; Ealick, S. E. The structure of human deoxycytidine kinase in complex with clofarabine reveals key interactions for prodrug activation. Acta. Crystallogr., Sect. D: Biol. Crystallogr. 2006, 62, 133-139.
24. Kabsch, W. Automatic processing of rotation diffraction data from crystals of initially unknown symmetry and cell constants. J. Appl. Crystallogr. 1993, 26, 795-800.
25. Vagin, A.; Teplyakov, A. MOLREP: an automated program for molecular replacement. J. Appl. Crystallogr. 1997, 30, 1022-1025.
26. Murshudov, G. N.; Vagin, A. A.; Dodson, E. J. Refinement of macromolecular structures by the maximum likelihood method. Acta Crystallogr. 1997, D53, 240-255.
27. Brunger, A. T.; Adams, P. D.; Clore, G. M.; Delano, W. L.; Gros, P.; Grosse-Kunstleve, R. W.; Jiang, J.-S.; Kuszewskli, J.; Nilges, N.; Read, R. J.; Rice, L. M.; Simonson, T.; Warren, G. L. Crystallography and NMR system (CNS): a new software system for macromolecular structure determination. Acta Ciystallogr 1998, D54, 905-921.
28. Jones, T. A.; Zhou, J. Y.; Cowan, S. W.; Kjeldgaard, M. Improved methods for building protein models in electron density maps and the location of errors in these models. Acta Crystallogr. 1991, A47 110-119.
29. Agarwal, K. C.; Miech, R. P.; Parks, R. E., Jr. Guanylate kinases from human erythrocytes, hog brain, and rat liver. Methods Enzymol. 1978, 483-490.